Brachytherapy
Volume 6, Issue 3 , Pages 173-179 , July 2007

The nature and extent of urinary morbidity in relation to prostate brachytherapy urethral dosimetry

  • Mischel Neill

      Affiliations

    • Department of Urology, Princess Margaret Hospital, Toronto, Canada
    • ,
  • Gabrielle Studer

      Affiliations

    • Department of Radiation Oncology, Princess Margaret Hospital, Toronto, Ontario, Canada
    • ,
  • Lisa Le

      Affiliations

    • Department of Biostatistics (LWL, GP), Princess Margaret Hospital, Toronto, Ontario, Canada
    • ,
  • Michael McLean

      Affiliations

    • Department of Radiation Oncology, Princess Margaret Hospital, Toronto, Ontario, Canada
    • ,
  • Ivan Yeung

      Affiliations

    • Department of Radiation Physics, Princess Margaret Hospital, Toronto, Ontario, Canada
    • ,
  • Greg Pond

      Affiliations

    • Department of Biostatistics (LWL, GP), Princess Margaret Hospital, Toronto, Ontario, Canada
    • ,
  • Juanita M. Crook

      Affiliations

    • Department of Radiation Oncology, Princess Margaret Hospital, Toronto, Ontario, Canada
    • Corresponding Author InformationCorresponding author. Department of Radiation Oncology, Princess Margaret Hospital, 610 University Avenue, Toronto, Ontario M5G 2M9, Canada. Tel.: +1-416-946-2919; fax: +1-416-946-2111.

Received 20 December 2006 ,Revised 9 March 2007 ,Accepted 20 March 2007.

References 

  1. Sherenz T, Wallner K, Wang H, et al. Long-term urinary function after transperineal brachytherapy for patients with large prostate glands. Int J Radiat Oncol Biol Phys. 2001;51:1241–1245
  2. Locke J, Ellis W, Wallner K, et al. Risk factors for acute urinary retention requiring temporary intermittent catheterization after prostate brachytherapy: A prospective study. Int J Radiat Oncol Biol Phys. 2002;52:712–719
  3. Crook J, Toi A, McLean M, et al. The utility of transition zone index in predicting acute urinary morbidity after 125I prostate brachytherapy. Brachytherapy. 2002;1:131–137
  4. Merrick GS, Butler WM, Wallner KE, et al. Long-term urinary quality of life following permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys. 2003;56:454–461
  5. Crook J, McLean M, Catton C, et al. Factors influencing risk of acute urinary retention after TRUS-guided permanent prostate seed implantation. Int J Radiat Oncol Biol Phys. 2002;52:453–460
  6. Terk MD, Stock RG, Stone NN. Identification of patients at increased risk for prolonged urinary retention following radioactive seed implantation of the prostate. J Urol. 1998;160:1379–1382
  7. Wallner K, Roy J, Harrison L. Dosimetry guidelines to minimize urethral and rectal morbidity following transperineal I-125 prostate brachytherapy. Int J Radiat Oncol Biol Phys. 1995;32:465–471
  8. Taussky D, Austen L, Toi A, et al. Sequential evaluation of prostate edema after permanent seed prostate brachytherapy using CT-MRI fusion. Int J Radiat Oncol Biol Phys. 2005;62:974–980
  9. Nath R, Anderson LL, Luxton G, et al. Dosimetry of interstitial brachytherapy sources: Recommendations of the AAPM Radiation Therapy Committee Task Group No. 43. American Association of Physicists in Medicine. Med Phys. 1995;22:209–234
  10. Merrick GS, Butler WM, Dorsey AT, et al. The dependence of prostate postimplant dosimetric quality on CT volume determination. Int J Radiat Oncol Biol Phys. 1999;44:1111–1117
  11. Zisman A, Leibovici D, Kleinmann J, et al. The impact of prostate biopsy on patient well-being: A prospective study of voiding impairment. J Urol. 2001;166:2242–2246
  12. Borboroglu PG, Comer SW, Riffenburgh RH, et al. Extensive repeat transrectal ultrasound guided prostate biopsy in patients with previous benign sextant biopsies. J Urol. 2000;163:158–160
  13. Gelblum DY, Potters L, Ashley R, et al. Urinary morbidity following ultrasound-guided transperineal prostate seed implantation. Int J Radiat Oncol Biol Phys. 1999;45:59–67
  14. Kang SK, Chou RH, Dodge RK, et al. Acute urinary toxicity following transperineal prostate brachytherapy using a modified Quimby loading method. Int J Radiat Oncol Biol Phys. 2001;50:937–945
  15. Merrick GS, Butler WM, Galbreath RW, et al. Relationships between the transition zone index of the prostate gland and urinary morbidity after brachytherapy. Urology. 2001;57:905–908
  16. Yue N, Dicker AP, Nath R, et al. The impact of edema on planning 125I and 103Pd prostate implants. Med Phys. 1999;26:763–767
  17. Shearer RJ, Davies JH, Gelister JS, et al. Hormonal cytoreduction and radiotherapy for carcinoma of the prostate. Br J Urol. 1992;62:521–524
  18. Forman JD, Kumar R, Haas G, et al. Neoadjuvant hormonal down-sizing of localized carcinoma of the prostate: Effects on the volume of normal tissue irradiation. Cancer Invest. 1995;13:8–15
  19. Hinerman-Mulroy A, Merrick GS, Butler WM, et al. Androgen deprivation-induced changes in prostate anatomy predict urinary morbidity after permanent interstitial brachytherapy. Int J Radiat Oncol Biol Phys. 2004;59:1367–1382
  20. Andersson KE. Storage and voiding symptoms: Physiological aspects. Urology. 2003;62:S3–S10
  21. Lee HK, D'Souza WD, Yamal JM, et al. Dosimetric consequences of using a surrogate urethra to estimate urethral dose after brachytherapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2003;57:355–361
  22. Allen ZA, Merrick GS, Butler WM, et al. Detailed urethral dosimetry in the evaluation of prostate brachytherapy-related urinary morbidity. Int J Radiat Oncol Biol Phys. 2005;62:981–987

PII: S1538-4721(07)00210-3

doi: 10.1016/j.brachy.2007.03.003

Brachytherapy
Volume 6, Issue 3 , Pages 173-179 , July 2007

Article Tools

* Image Usage & Resolution